2022 ASCO GI Annual Meeting

January 12, 2023

Haystack is looking forward to attending the ASCO Gastrointestinal Cancers Annual Symposium taking place January 19-21 in San Francisco, CA. ASCO GI will be celebrating 20 years of offering the latest innovative science, solution-focused strategies, and multidisciplinary approaches in GI cancer treatment, research, and care. If you’re there, please stop by table #43 and learn about Haystack’s MRD test that delivers unmatched ctDNA detection sensitivity and accuracy for superior post-surgical treatment management.

Subscribe for updates

No spam, notifications only about new products, updates.

News and events

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

July 18, 2024

Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of best-in-class personalized MRD technology (Haystack MRD™), has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development

Haystack technology in action at ASCO 2024!

June 18, 2024

Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology’s personalized MRD technology (Haystack MRD™) to analyze therapeutic response and provide molecular insights for AFT’s

More news and events

Follow us on social media

Purpose-built, high-precision MRD testing

Connect with us

Your Privacy Choices

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.